Objectives: The purpose of this study was to test the transcutaneous noninvasive vagus nerve stimulator (nVNS) (gammaCoreV C ) device to determine if it modulates the peripheral immune system, as has been previously published for implanted vagus nerve stimulators.
INTRODUCTION
The vagus nerve (cranial nerve X) is the primary neural component of the parasympathetic nervous system. It is a critical mediator of physiological homeostasis due to its control of heart rate, motility, and secretion of the gastrointestinal tract, pancreatic endocrine and exocrine secretion, hepatic glucose production, and other visceral functions. Importantly vagal activity suppresses innate immune and inflammatory responses to pathogen invasion and tissue injury (1) (2) (3) . Growing evidence suggests that the innate immune response malfunctions and becomes excessively activated in inflammatory immune-mediated diseases such as rheumatoid arthritis (RA), psoriatic arthritis, and psoriasis (4) (5) (6) . Furthermore, vagal dysfunction may contribute to the excessive inflammation in RA while vagal nerve stimulation may reduce inflammation in RA (7) (8) (9) . Recently, hyperinflammatory response has been implicated in the pathophysiology of post-traumatic stress disorder (10, 11) and depression (12) . Vagal mediated signaling to the adrenal cortex and heart can reduce cortisol secretion and increase heart rate variability supporting a role for vagal mechanisms in stress disorders (13) (14) (15) (16) .
Pathogen-associated molecules are recognized by sensor/ receptors on the nodose ganglion or immune cell surfaces or in intracellular compartments through toll-like receptors (TLRs), nucleotidebinding oligomerization domain-like receptors (NLRs) (17) (18) (19) , and IL-1b receptors (20) (21) (22) (23) (24) . These receptors may individually or collectively activate signal cascades that stimulate release of proinflammatory cytokines and C-reactive protein (CRP) (2, 25) (Fig. 1a ). Chavan and associates (26) showed that three minutes after intraperitoneal tumor necrosis factor (TNF) injection, mouse vagus nerve firing increased up to approximately 36 Hz from a baseline median firing rate of approximately 7 Hz. Others have shown an increase in vagal afferent firing frequency in response to hepatic IL-1b administration (27) . Efferent vagal action potentials transmit to the celiac mesenteric ganglion and signal post-ganglionic sympathetic splenic nerves to release norepinephrine, however specific mechanisms of this signaling process remain controversial (28) (29) (30) . Although debated, splenic release of norepinephrine (NE) may activate b adrenergic receptors on splenic T cells that express choline acetyltransferase (ChAT) (31) , and synthesize acetylcholine (ACh). ACh then binds to and activates nicotinic acetylcholine receptor subunit a7 (a7nAChR) that are expressed on the membrane of innate immune cells within the spleen. ChAT 1T cells are known to be necessary for a7nAChR signaling, which inhibits nuclear factor kappa B (NFjB) activation both directly and indirectly by activating STAT3, thereby decreasing expression of TLR4 and suppressing transcription of inflammatory cytokines (Fig. 1b) (32) (33) (34) (35) (36) (37) (38) . Nude mice lacking T cells, also lack cholinergic anti-inflammatory capacity, further supporting the hypothesis that ChAT 1T cells are pivotal in a7nAChR signaling (31). Tracey and associates (1-3), describe this vagus nerve, ACh mediated anti-inflammatory pathway, as the cholinergic anti-inflammatory pathway (CAP). Vagal nerve stimulation by CAP decreases leukocyte trafficking through suppression of b-integrin CD11b, thereby decreasing the number of cells which respond to inflammatory chemokine signals (39) . More recently, ACh transport through pores on the immune cell membrane directly to mitochondria was demonstrated. ACh activation of a7nAChR inhibited mitochondrial DNA release, which in turn decreases NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasome synthesis of cytokines such as IL-1b and IL-18 (40) . Taken together, current preclinical literature supports neuroinflammatory reflexes mediated by vagus nerve signaling result in anti-inflammatory effects thought to be relevant in human models of inflammation.
TNF, IL-6, and lipopolysaccharide (LPS) stimulate the hypothalamic-pituitary-adrenal (HPA) axis, resulting in increased production of cortisol that constrains immune responses to prevent excess inflammation (23, 41, 42) . This stimulation of HPA hormone secretion is due, in part, to afferent vagal fiber activation of the nucleus tractus solitarius [NTS]-to-paraventricular nucleus [PVN] neurocircuit culminating in adrenocorticotropic hormone (ACTH) and subsequent adrenocortical secretion of cortisol (Fig. 1b) . Preclinical studies show that bilateral cervical vagotomy significantly inhibits LPS-induced increase in corticosterone, confirming the importance of the afferent vagal-to-NTS-to-PVN pathway in HPA regulation (33) . If stress-induced HPA secretion of glucocorticoids is insufficient to control inflammation, as may occur in inflammatory disorders such as RA, hypersecretion of proinflammatory cytokines from immune cells may abnormally persist (10, (43) (44) (45) (46) (47) (48) (49) .
Similar to in vivo pathogen-mediated activation, electrical stimulation of the vagus results in a decrement of multiple inflammatory cytokines (e.g., TNF, IL-6, IL-8) (33, 50) . Mixed results have been reported for the anti-inflammatory cytokine IL-10 (33,50,51). Thus, vagus nerve stimulation is emerging as a potential treatment for human inflammatory diseases (16, 50, (52) (53) (54) .
Preclinical bilateral stimulation of the vagus with distal anesthetic blockade (with presumably afferent-only signaling) exerts antiinflammatory effects (50) , which may result in part from corticosteroids secretion. Interestingly, anti-inflammatory effects seen during bilateral cervical vagotomy followed by afferent only vagal stimulation are dependent on an intact splenic nerve. It is known that the vagal-to-NTS-to-PVN pathway also sends efferent fibers to the Locus Coeruleus (LC) (vagal-to-NTS-to-PVN-to-LC pathway) and then to the sympathetic trunk via the intermediolateral cell column (54) . Sympathetic trunk-derived splanchnic nerves signals to the celiac ganglion and then via splenic nerve to the spleen release norepinephrine known to activate the aforementioned CAP, and immune cell b adrenergic receptors that inhibit cytokine production through suppressing NFjB (23) . Anti-inflammatory effects shown with bilateral cervical vagotomy and afferent only vagal nerve stimulation depend on an intact splenic nerve suggest that the vagal-to-NTS-to-PVN-to-LC pathway is a critical component of the inflammatory reflex (55) .
Extrapolating from these preclinical and emerging clinical studies, we hypothesize that nVNS using the gammaCore device at 25 Hz may encode specific vagal nerve signaling in afferent-to-efferent and efferent pathways that may result in alteration of peripheral inflammation in healthy control subjects.
MATERIALS AND METHODS

Study Subjects
Twenty subjects were recruited through the Clinical and Translation Research Institute (CTRI) at the University of California, San Diego Health System and randomly assigned to receive either nVNS or SST. All subjects were between the ages of 18 and 61 years, were deemed healthy by medical and physical examination, and did not take any chronic medications. There were 10 active and 10 sham subjects, with an equal ratio of male to females 6:4. Subjects were instructed to refrain from taking any over-the-counter analgesics or anti-inflammatory medications (e.g., nonsteroidal anti-inflammatory drugs and acetaminophen), tobacco products, or alcoholic beverages for one week prior to the study visit. Subjects with prior surgery or abnormal anatomy at the gammaCore V R treatment site, history of neurologic disease (including transient ischemic attack, seizures, and syncope), and history of cardiovascular disease were excluded from LERMAN ET AL. 
Intervention
Subjects were randomly assigned to receive either SST or nVNS. The nVNS device produced a low-voltage electrical signal (5-kHz sine wave series that occurred for 1 ms and repeated every 40 ms [25 Hz]). Upon application of the device to the neck, it delivered a maximum of 24 V and 60 mA output current while allowing stimulation amplitude adjustment by the user. Two stainless steel contact surfaces and conductive gel applied by the user enabled delivery of stimulations. In both sham and nVNS treatment paradigms, the principle investigator instructed the subject to place the device just under the angle of the mandible, lateral to the trachea and medial to the sternocleidomastoid. In both the nVNS and SST device, there was an initial 30-sec ramp up period, resulting in a total of 90 sec of actual stimulation per two-minute stimulation session. The SST device was identical in appearance, and carried out the same period of stimulation but differed in stimulation parameters with a slowly varying DC signal (.1 Hz) with maximum range of 6 14 V that produced a slight skin tingling sensation. Voltages for sham and active nVNS device were recorded for each stimulation session (Table 1) .
Research Design
Subjects were required to be present at the CTRI research facility for two visits during two consecutive days. Subjects underwent an initial blood draw at 8:00 AM, followed 30 min later by stimulation with either nVNS or SST. Stimulation for either case lasted for two minutes, on first the right and then the left side. Left side stimulation was carried out five minutes after right side stimulation. Blood was then drawn at 10:30 AM, 90 min after the 8:30 AM stimulation. The subject was instructed to deliver the stimulation sequence (once per side) at noon and again at 6:00 PM the same day and return to the CTRI research facility the following morning. On the second day, site staff ascertained any changes to subject's medical history or adverse events, electrocardiographic findings, and vital signs and performed a physical examination. A final third blood draw occurred at 8:00 AM on the second day. The primary endpoints of this study were detection of percent change in cytokines measured with or without additive LPS in whole blood that was cultured for 24 hours (within each group, [nVNS or SST], and between groups).
Serum Collection
Blood was drawn using TruCulture RBM system. Blood samples were obtained at CTRI in a sterile manner, and two 1-mL aliquots (one tube without LPS and one tube with LPS added) of whole blood were cultured for 24 hours at 378C then stored at 2808C. Cytokine and chemokines were collected using a human cytokine multiplex immunoassay (Myriad Rules-Based Medicine Inc., Austin, TX). LPS tubes had 0.1 lg/mL or 100 ng/mL of LPS in each 1 mL whole blood cultured tube. The multiplex microbead assay is based on Luminex technology and measures proteins similarly to standard sandwich enzyme-linked immunosorbent assay, with comparable sensitivity and range. The lower limit of quantitation (LLOQ) for the cytokines were:
• MCP1: 87 pg/mL • MIP-1a: 28.0 pg/mL • MIP-1b: 60.0 pg/mL • TNF: 15.0 pg/mL • IL-1b: 6.6 pg/mL • IL-6: 11.0 pg/mL • IL-10: 4.9 pg/mL immune cell surface or in intracellular compartments through both Toll-like receptors (TLRs), nucleotide binding oligomerization domain-like receptors (NLRs), which activate signal cascades that result in release of proinflammatory cytokines. Pro-inflammatory cytokines may activate vagal afferent fibers in the periphery and within vagal paraganglia cells, as well as act on the area postrema (AP). b. Activated vagal afferents transmit from NTS to the DMN, to efferent vagal fibers that transmit to Celiac Ganglion then to splenic nerve resulting in ChAT 1T cell release of the neurotransmitter acetylcholine (Ach), which interacts with innate immune cells that express the nicotinic acetylcholine receptor subunit a7 (a7nAChR). Activated a7nAChR inhibits nuclear factor kappa B (NfjB) activation both directly and indirectly via Signal Transducer and Activator of Transcription 3 (gene) (STAT3), resulting in decreased expression of TLR4, and suppresses transcription of inflammatory cytokines (red X). Cytokines activate the HPA axis via TLR4 receptors and presumed IL-6 receptors found on vagal paraganglia cells and the Area Postrema (AP), resulting in increased production of cortisol that protects against excess inflammation. Vagal-to-NTS-to-PVN pathway also sends efferent fibers to the Locus Coeruleus (vagal-to-NTS-to-PVN-to-LC pathway) via the sympathetic trunk, and splanchnic nerve signal to the celiac ganglion and then to splenic nerve to activate b adrenergic receptors (bAR) and the cholinergic anti-inflammatory pathway (CAP The LLOQ is the lowest concentration of an analyte in a sample that can be reliably detected and at which the total error meets the laboratory's requirements for accuracy (56) . TruCulture tubes were sent Myriad RBM, where multianalyte profiling assays were performed using human inflammation MAP-A and MAP-B technology.
Statistical Methods
We compared independent samples with the Mann-Whitney U test and paired samples with the Wilcoxon Signed-rank test. All calculations were performed using the open source statistical programming language R (www.r-project.org).
RESULTS
Subjects
Subject groups were similar in age, sex, body mass index, heart rate, and blood pressure ( Table 1 ). The average age of the cohort was 36 6 14 years for the sham group and 35.8 6 14.5 years for the treated group. The study population was composed of 65% Caucasian, 30% Asian, and 5% African American individuals. Adverse events were minor during stimulation and equal across both groups, with headache and pain during stimulation noted most commonly (Table 1) . One male subject who reported muscle strain and persistent pain at the stimulation site was excluded on the second visit day. A second female subject was excluded due to difficulty with blood draw. After subject exclusion, the male to female ratio was 6:4 (Table 1) .
Cytokine Analyses
Within Group Non-LPS-Stimulated Whole Blood Culture Cytokine Analysis At 90 min, there was no significant percent decrease compared to baseline in any cytokine or chemokine levels within the SST group in non-LPS-stimulated whole blood culture (n-WBCx) (Fig. 2) . The SST group did, however, demonstrate a significant percent increase in the chemokine IL-8 (p < 0.05) at this time. At the 24-hour time point all of the levels in SST subjects were comparable to baseline, while in the nVNS group, n-WBCx demonstrated a significant percent decrease in cytokine (IL-1b, TNF) and chemokine (MIP-1a, MCP-1, IL-8) levels (p < 0.05) (Fig. 3) . Within the nVNS group, IL-6 levels had a strong tendency to decrease at the 24-hour time point (p < 0.06) (Fig. 3) .
Between Group n-WBCx Cytokine Analysis
Raw baseline (prior to stimulation) n-WBCx cytokine and chemokine values did not differ between groups (p > 0.1), except for the cytokine IL-1b, which was elevated in the nVNS group (p 5 0.041) (Supporting Information Table 1 ). Compared to the SST group, the nVNS group had a greater percent decrease in the chemokine IL-8 concentration (p < 0.05) at 90 min (Fig. 2) . At this time cytokines, IL-6 and Il-1b approached a significant decrease when the nVNS group was compared to SST (p < 0.06). Compared with the SST group, the nVNS group had a significantly greater percent decrease in cytokine (IL-1b, TNF) and chemokine (MCP-1, IL-8) levels at 24 hours (p < 0.05).
LPS-Stimulated Whole Blood Culture Analysis
LPS-stimulated cytokines and chemokines did not differ significantly in the nVNS vs. SST, (Supporting Information Figs. 1 and 2) , except for IL-10, which increased at 24 hours in the nVNS group when compared to the SST group (p < 0.005) (Fig. 4) . Raw baseline (prior to stimulation) L-WBCx cytokine and chemokine values did not differ between groups (p > 0.1).
DISCUSSION
In this pilot study, nVNS significantly decreased the release of proinflammatory cytokines in whole blood culture when compared to sham stimulation.
Data from Tracey (1) indicate that afferent vagal-mediated signals are relayed to the NTS and that the Dorsal Motor Nucleus (DMN) activates vagal efferents targeted to the celiac ganglion, thereby stimulating the CAP (deactivating monocytes) and resulting in decreased release of peripheral cytokines. Vagus nerve stimulation is believed to mediate an anti-inflammatory effect through: 1) induction of the CAP via ChAT 1T cells, altered cytokine expression, either through ACh ligand-induced activation of a7nAChRs on the cell membrane or in mitochondria that modulate the NLRP3 inflammasome and inhibit procaspase-1; 2) activation of the NTS-to-PVN pathways, resulting in ACTH stimulation of adrenocortical release of glucocorticoids; 3) activation of the NTS-to-PVN-to-LC pathway ultimately signaling to splenic nerve resulting in norepinephrine release that can activate the CAP via ChAT 1T cells and immune cell b adrenergic receptors that can inhibit cytokine production; and 4) decreased leukocyte trafficking through suppression of b-integrin CD11b, thereby decreasing the number of circulating leukocytes able to mobilize to an inflammatory chemokine signal. Vagus nerve electrical stimulation mediated by these potential pathways has been shown to decrease peripheral inflammation, evidenced by a reduction in multiple inflammatory cytokines, including TNF, IL-6, and IL-8, and CRP in dogs (57) and humans (52) . The pilot data in our study support the anti-inflammatory effect of nVNS, likely due to activation of the CAP, with a significant percent decrease in IL-8 at 90 min (Fig. 3 ) and significant percent decreases in cytokine and chemokine levels at the 24-hour time point (Fig. 4) .
The SST group did not demonstrate a significant percent decrease in any measured cytokine or chemokine levels at either the 90-min or 24-hour poststimulation n-WBCx. Instead the SST group had an increase in IL-8 at 90 min (Fig. 3) .
Cytokine concentrations vary over a 24-hour period with circadian rhythm. The circadian rhythm of inflammatory cytokines is believed to be controlled by central gene expression clocks activated via the suprachiasmatic nucleus and the hypothalamus, which induce entrainment of peripheral clock inflammatory cytokine gene expression as well as release of peripheral cortisol by way of paraventricular nucleus ACTH signaling to the adrenal cortex to release cortisol (58) . Beyond cytokine synthesis and release, the number of inflammatory cells also has a circadian rhythm, with monocyte nadir occurring at 8:00 AM and acrophase (peak cells per milliliter) at 11:00 PM (59) . Inflammatory disease states such as RA, bronchial asthma, allergic rhinitis, ankylosing spondylitis, and polymyalgia rheumatica demonstrate early morning increases in symptom severity. In RA, bronchial asthma, and polymyalgia rheumatica symptom, severity has been correlated with a clear early morning circadian increase in inflammatory cytokines (14) . Sham stimulation in our study resulted in a significant percent increase in IL-8 when comparing the 8:00 AM and 10:30 AM draws, coinciding with likely circadian rhythmicity of this cytokine. In contrast, the nVNS group showed a percent decrease in all cytokines, although it was not statistically significant at the 10:30 AM draw. The three stimulation sessions in nVNS group resulted in a significant percent drop in MIP-1a, MCP-1, TNF, IL-1b, and IL-8 at the 24-hour time point. The 24-hour collection point controlled for individual differences due to circadian alterations in cytokine expression because blood draws were recorded at the exact same time each day (8:00 AM). It is possible that if a larger number of study subjects were enrolled there may have been a 90-min decrease in cytokines in the nVNS group.
This cohort of healthy volunteers did not show any reduction in LPS-stimulated whole blood cultures (L-WBCx), although this has been reported in preclinical literature (33, 50) . The primary difference between these preclinical studies and the current study are use of surgically implanted vagus nerve stimulators and in vivo administration of LPS. In vivo LPS administration results in the recruitment and activation of circulating monocytes that may subsequently undergo modulation when circulated through the spleen. The healthy control cohort in our study did not demonstrate signs of illness and, therefore, were unlikely to have increased recruitment and mobilization of immune cells that decreased the measured effect of LPS in culture. Peak cytokine levels are dependent on culture time when stimulated with LPS, which may not have been captured in a 24-hour culture. The only cytokine that increased in the L-WBCx was IL-10 in the nVNS group. IL-10 acts on immune cells, including monocytes/macrophages at IL-10R1, and IL-10R2 through STAT3, resulting in decreased synthesis of cytokines such as TNF, IL-1b, IL-6, and the chemokine IL-8 (60) (61) (62) . Taken together, IL-10 has the potential to inhibit inflammatory cytokine and chemokine synthesis and release. nVNS treatment greater than one day (as in the current study) may result in further IL-10 anti-inflammatory effects in LPS mediated culture.
Limitations
Because this pilot study involved only ten subjects per group, the small sample size may not adequately represent a larger population, which could skew the results. Nonetheless, these positive findings in such a small cohort of healthy control subjects were robust and significant warranting further investigation on peripheral immune system effects of transcutaneous nVNS in larger cohort of healthy control subjects as well as in subjects with inflammatory immunemediated diseases. In our future research, we plan to quantify mRNA transcript levels as careful RNA sequencing and analysis may provide important insight into nVNS regulation of immune gene expression. Although the target of this stimulator is the vagal nerve, cutaneous afferents to the skin and innervation of the underlying tissue may have been stimulated as well. Further studies that block cutaneous afferents and or underlying tissue may elucidate target specific mechanisms of transcutaneous cervical stimulation as delivered by the gammaCore device.
CONCLUSION
For the first time to our knowledge, we show transcutaneous nVNS modulates human inflammatory cytokines and chemokines, as measured by WBCx. The significant decrement in cytokines and chemokines seen in this study supports the concept that such stimulation activates cholinergic-mediated anti-inflammatory responses the vagal NTS-PVN-HPA and NTS-PVN-LC pathway. Other as yet undiscovered reflex pathways might also contribute. Future studies will focus on nVNS anti-inflammatory mechanisms in immune-mediated inflammatory diseases that may eventually lead to a viable nVNS anti-inflammatory therapy.
COMMENTS
The purpose of this pilot study was to determine if VNS modulates the peripheral immune system (b and TNFa) in whole blood culture when compared to sham stimulation. These data have potential therapeutic implications in the domain of inflammatory disorders based on the anti-inflammatory properties of the VN.
Indeed, the VN activates the hypothalamic-pituitary-adrenal axis through the activation of vagal afferents by peripheral pro-inflammatory cytokines that convey the peripheral immune information to the nucleus tractus solitarius (NTS) in the brainstem thus activating noradrenergic neurons in the NTS that project to the paraventricular nucleus of the hypothalamus around corticotrophin-releasing (CRF) neurons. The release of CRF will then activate the release of ACTH by the hypohysis then stimulating the release of glucocorticoids by the adrenal glands [1] . It is termed the neuro-endocrine-immune axis. More recently, an anti-inflammatory role of vagal efferents has been described by the group of KJ Tracey. Using a model of endotoxic shock in rats [2] , they showed that the release of TNFa was increased both in the blood and in the liver and this TNFa level was increased in vagotomized animals. In contrast, when performing VNS of the distal end cut of the VN, activating for sure vagal efferents, they dampened the release of TNFa. They argue for an inflammatory reflex as represented by a vago-vagal reflex, called the cholinergic anti-inflammatory pathway [see for review Ref. 3] . They showed that this anti-inflammatory reflex was mediated through the binding of acetylcholine (ACh), the neuromediator of the VN, with a7-nicotinic ACh receptors (a7nAChR) of macrophages since this effect was blunted in a7 knockout animals [3] . This group also argues for an interaction of the VN with the sympathetic splenic nerve that innervates the spleen. Activation of the VN was supposed to inhibit the release of TNFa by spleen macrophages where norepinephrine released at the distal end of the splenic nerve was able to act on b2 adrenergic receptor of spleen lymphocytes to release ACh then activating a7nAChR of spleen macrophages to inhibit the release of TNFa [3] . This anti-inflammatory spleen pathway has been revisited recently by Martelli et al. [4] . Another pathway could be the activation of sympathetic nerves by the central autonomic nervous system through the integration of peripheral inflammatory signals in the brain by vagal afferents then stimulating descending pathways that activate the spinal pre-ganglionic sympathetic neurons [5] . Thus the VN has an anti-TNFa effect and its activation by VNS, originally used to treat drug-resistant epilepsy through stimulation of vagal afferents, could be used in TNFa-mediated diseases such as inflammatory bowel diseases (IBD; Crohn's disease and ulcerative colitis), rheumatoid arthritis, psoriasis as well as other inflammatory conditions such as pancreatitis and postoperative ileus [6] . Most of these diseases are characterized by an imbalance of the autonomic nervous system as represented by a blunted vagal tone in IBD [7] . Thus VNS, by restoring a normal vagal tone, could be an interesting tool in the armamentorium to treat such diseases. In particular, VNS could be an alternative nondrug therapy to classical anti-TNFa drugs. Invasive VNS used in the treatment of drug resistant epilepsy is performed through a spiral electrode wrapped around the left cervical VN, because the right VN innervates the sinoatrial node (involved in the pace-maker function of the heart), then tunneled subcutaneously to and connected with a pulse generator located in the left chest wall [6] . The implantation (~1h duration) is performed under general anesthesia generally by neurosurgeons familiar with epilepsy. The VNS device is manufactured by Cyberonics (Houston, TX, USA). Using this device and based on preliminary data in animals with colitis [8] , we reported the first case of VNS in a patient with Crohn's disease [9] , and we have very recently shown that VNS could be of interest in mild to moderate Crohn's disease [10] . Non-invasive VNS eliminating the need for surgical implantation and thus improving the safety and tolerability of VNS is of interest. The cymba concha of the external ear is innervated exclusively by the auricular branch of the VN that projects to the NTS. Transcutaneous auricular VNS (ta-VNS), by activating the inflammatory reflex could be used in the management of inflammatory disorders. Ta-VNS has been shown to protect endotoxemic rat from lipopolysaccharide-induced inflammation [11] . Ta-VNS using the device NEMOS (Cerbomed, Erlangen, Germany) has been used in the management of refractory epilepsy [12] . GammaCore (electroCore LLC, Basking Ridge, NJ, USA) is another non-invasive VNS that uses proprietary electrical signals to treat primary headache [13] . It consists of a portable stimulator with a battery, signal-generating and -amplifying electronics and a digital control user interface that controls signal amplitude. Two stainless steel round discs function as skin contact surfaces that deliver a proprietary, low-voltage electrical signal to the cervical VN. Such a device could be used in the treatment of inflammatory disorders.
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